Plecanatide for the treatment of constipation-predominant irritable bowel syndrome

  title={Plecanatide for the treatment of constipation-predominant irritable bowel syndrome},
  author={Philip B. Miner},
  journal={Expert Review of Gastroenterology \& Hepatology},
  pages={71 - 84}
  • P. Miner
  • Published 27 January 2020
  • Medicine
  • Expert Review of Gastroenterology & Hepatology
ABSTRACT Introduction: As an analogue of uroguanylin plecanatide binds to the Guanylate Cyclase-C receptor activating fluid and ion secretion in the small intestine with the same pH-dependent binding kinetics as the natural ligand. Plecanatide has been FDA approved as safe and effective for the indications of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C). Areas covered: All clinical trial results supporting approval of plecanatide in IBS-C are… 


Benefit–Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation
Clinical data from studies of recently approved drugs for CIC are utilized to construct a platform for thoughtful understanding of CIC and of how changes in investigation guidelines influence the interpretation of study data and guide symptom management.
An update on prucalopride in the treatment of chronic constipation
One such agent is prucalopride, which has now been approved for the management of chronic idiopathic constipation in several countries, but not in the United States, and has enjoyed a favorable safety profile and there have been no signals to suggest arrythmogenicity.
Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders
This review focuses on the evolving understanding of GC-C function in health and disease, and strategies for translating these principles into new treatments for FGIDs and IBDs.
Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation
Over the 12 weeks, plecanatide significantly improved stool consistency and stool frequency, and was well tolerated; the most common AE, diarrhea, occurred in a small number of patients.
A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation
Results suggest that plecanatide will be a useful treatment option in the management of CIC and significantly improved constipation and its related symptoms with a low rate of adverse events.
Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
Tenapanor 50 mg b.i.d. significantly increased stool frequency and reduced abdominal symptoms in patients with IBS-C, and further research into tenapanor as a potential treatment for these patients is justified.
Long-term treatment with plecanatide was safe and tolerable in patients with irritable bowel syndrome with constipation
Plecanatide 6 mg was safe and well tolerated in patients with IBS-C treated for up to 53 weeks, with an overall safety profile similar to the 12-week IBS -C studies.
Plecanatide, an Oral Guanylate Cyclase C Agonist Acting Locally in the Gastrointestinal Tract, Is Safe and Well-Tolerated in Single Doses
Plecanatide, an oral GC-C agonist, acting locally within the GI tract without measurable systemic exposure, was safe and well-tolerated in single doses up to 48.6 mg.
Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation
  • P. Miner
  • Medicine
    Expert opinion on pharmacotherapy
  • 2018
The early phases of elobixibat development provide confirmation of high IBAT binding affinity which translates into the expected inhibition of enterohepatic bile acid circulation and enhanced delivery of ileal bile acids to the colon associated with expected physiological changes.
Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials
Plecanatide significantly improved both abdominal pain and constipation symptoms of IBS‐C with minimal associated side effects and high levels of tolerability.